Why Bill Gates and Jeff Bezos Bet $188 Million on LifeMine

LifeMine Therapeutics has raised a $188 million Series E investment from Bill Gates and Jeff Bezos. The funding was three to four times the amount the company had initially targeted. The Massachusetts-based clinical-stage biotechnology company plans to use the investment to restart its previously suspended fungal-genome-based drug discovery platform and begin a phase 2 trial in early 2027 involving 150 kidney transplant recipients.

LifeMine cut its workforce last year because of financial difficulties and focused solely on developing its lead compound after halting operations of its fungal platform. In that situation, CEO Gregory Verdine explained the platform’s potential directly to Bill Gates and Jeff Bezos during a Zoom video meeting. The two billionaires led an investment well above the target amount, saying, “Greg, you absolutely have to bring this platform back.”

■ A drug discovery platform born from 1 billion years of evolution

LifeMine’s core competitive advantage is its proprietary “Top-Down” platform, which analyzes the genomes of more than 100,000 fungi to identify drug candidates. The approach applies potent small-molecule compounds evolved by fungi over 1 billion years to the treatment of human diseases. The platform has identified 1,200 potential drug targets. With the new investment, LifeMine plans to combine artificial intelligence (AI) with the platform to accelerate target selection.

■ Targeting the limitations of a 30-year-old immunosuppressant

More than 1.6 million people worldwide live with transplanted organs, and 90% of them rely on tacrolimus, the standard treatment. The problem is that existing calcineurin inhibitors, including tacrolimus, can cause nephrotoxicity, metabolic disease and cardiovascular adverse effects. The standard treatment protocol has remained essentially unchanged for more than 30 years because no safe drug has emerged to replace it.

LifeMine’s lead compound, “LIFE-001,” is a calcineurin activation inhibitor (CNai) designed to act directly by bypassing the pathway through which existing drugs act via a mediator protein that causes toxicity. In a phase 1 trial involving more than 120 healthy adults, no renal, metabolic or cardiovascular toxicity was observed at therapeutic doses. Verdine said, “Particularly in the islet transplantation field, this drug could be the key to curing diabetes.”

■ Market potential and clinical roadmap

If LIFE-001 is successfully commercialized, the company estimates that it could generate sales of as much as $25 billion to $30 billion in the organ transplantation field alone. LifeMine plans to begin a phase 2 trial in early 2027 involving 150 kidney transplant recipients and directly comparing the drug with tacrolimus. At the same time, it plans to conduct a 12-patient phase 1b trial targeting islet transplantation in patients with severe diabetes and announce key data around late 2027 to 2028.

Including the Series E, LifeMine’s cumulative private investment totals approximately $580 million. Adding the previously disclosed $75 million Series D and the $188 million Series E brings the company’s funding from its most recent rounds alone to $263 million. Industry observers expect that positive kidney transplant clinical data could lead to expansion into liver, lung and heart transplantation, as well as autoimmune diseases such as ulcerative colitis, followed by licensing deals with global big pharmaceutical companies and a Nasdaq initial public offering (IPO).